The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.
Milestone Pharmaceuticals, Inc. is looking at a significant potential commercial opportunity with positive results from its Phase III study of etripamil in paroxysmal supraventricular tachycardia (PSVT), given that the drug would be the first self-administered therapy for a condition that usually requires care in a hospital.
Milestone announced the results of the Phase III RAPID trial on 17 October, and the company added it plans to...
CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”
Detailed clinical trial data presented at AHA positions the oral PCSK9 inhibitor on par with injectable drugs on efficacy, but the competitive dynamics remain intense.
Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.
A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.
The biopharma plans to advance the PD-1 agonist in rheumatoid arthritis despite its failure in ulcerative colitis.
Small study fails to turn up efficacy signals in the major depressive disorder candidate, leaving Neurocrine with one remaining depression candidate in development.
